Clinical Trial Results:
A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and correlative science studies attempting to identify predictors of response
Summary
|
|
EudraCT number |
2012-004956-12 |
Trial protocol |
IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Sep 2021
|
First version publication date |
24 Sep 2021
|
Other versions |
|
Summary report(s) |
Documento per EUDRACT_signed |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.